ArisGlobal debuts XDI and NavaX AI platform to streamline regulated R&D, aiding Anavex Life Sciences

ArisGlobal unveils integrated AI platform for life sciences

AI Cortex for Regulated R&D

ArisGlobal is rolling out a suite of AI products aimed at standardizing and accelerating regulated R&D workflows across biopharma, a development directly relevant to companies such as Anavex Life Sciences that run global clinical programs and safety monitoring. The centerpiece, XDI, is a system‑agnostic data intelligence cortex that accesses data across Safety, Regulatory, Clinical, Quality and Manufacturing functions to provide consistent, explainable decisions grounded in shared meaning, context and intent. ArisGlobal frames XDI as an explainable AI layer that reduces interpretive drift and operational risk by aligning evidence and governance across enterprise functions.

Complementing XDI, ArisGlobal expands its NavaX Agents Suite with three purpose‑built agents and introduces NavaX Translation to streamline pharmacovigilance (PV) intake workflows. Intelligence Agents automatically interpret evolving regulatory guidance into checklists and apply them to LifeSphere Submissions with compliance evaluations, justifications and confidence scores to lift submission quality. Distribution Agents continuously validate distribution logic against new guidance and trigger governed change workflows when discrepancies arise. Signals Agents act as an active intelligence partner that interprets user intent, selects analytical approaches and orchestrates cross‑functional reasoning across safety, data and expert judgment. NavaX Translation, built with TransPerfect Life Sciences, embeds certified translation into case intake, routing non‑English safety forms to pharma‑specific language models and expert linguists and returning translated forms via API in under a minute versus an average manual handling time of about five hours.

For small and mid‑sized biotech firms like Anavex, the package is positioned to materially cut manual review, speed adverse event processing and improve audit readiness. The combined platform is designed to deliver traceable, governed decisions for sponsors and CROs, reducing cycle times in submissions and pharmacovigilance while enabling distributed teams to operate against a single evidence baseline. Operational gains include faster signal detection, more consistent regulatory filings and the ability to scale global safety operations without proportionally increasing headcount — subject to each sponsor’s validation and governance processes.

Translation partnership shortens case processing

The TransPerfect Life Sciences tie‑up embeds certified translation at intake, which ArisGlobal says cuts translation management from roughly five hours per case to under a minute by leveraging language detection, specialized models and expert linguists via API into LifeSphere, accelerating global PV throughput.

Governance, explainability and enterprise adoption

ArisGlobal emphasizes explainable AI, continuous compliance validation and governed change workflows to support audit‑ready traceability. The company positions these features as enabling confident enterprise adoption by aligning evidence and decision logic across Safety, Regulatory, Clinical and Commercial functions.